RJA
TOVX icon

Raymond James & Associates’s Theriva Biologics TOVX Stock Holding History

Raymond James & Associates’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2
Closed -$5K – 3716
2018
Q2 		$5K Hold
2
– – ﹤0.01% 3547
2018
Q1 		$4K Buy
+2
New +$7.61K ﹤0.01% 3437

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Raymond James & Associates's TOVX Position: Q3 2018 in Review

Raymond James & Associates sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 2 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in TOVX in Q1 2018 and held it in 2 quarters. The position peaked at $5K in Q2 2018. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

  • Raymond James & Associates reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 2 Theriva Biologics shares in Q3 2018, an estimated $5K.
  • Raymond James & Associates first reported a position in Theriva Biologics in Q1 2018 and held it in 2 quarters.
  • Raymond James & Associates's Theriva Biologics position peaked at $5K in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.